AXSOME THERAPEUTICS INC

Axsome CEO Thomas Herriot buys shares at $4.95, sells them at $212+, signaling long‑term confidence in the drugmaker’s pipeline and value potential.

Insider activity reveals CEO Tabuteau Herriot’s disciplined 10‑b5‑1 plan: buying undervalued shares and selling at peak highs, giving investors insight into Axsome’s strategy and risk‑adjusted upside.

Axsome insider sales: Roger Jeffs’ June 10th trade is a routine tax‑management move, not a warning. Understand how modest RSU‑based selling keeps leadership aligned.

Insider buys signal confidence in Axsome’s pain & CNS pipeline – a bullish trend amid strong market gains, social buzz, and upcoming trial data.

Axsome insider activity: Director Coleman Mark’s 1,721‑RSU buy signals confidence amid a 13.5 % monthly rally and rising social‑media buzz, hinting at long‑term upside and strategic alignment with shareholders.

Insider sale at Axsome shows disciplined option liquidation, not a sell‑off; long‑term holders remain, reflecting confidence in pain‑management growth.

Axsome COO’s routine 10b5‑1 trades reveal a balanced insider stance—no red flag, just portfolio rebalancing amid a strong pipeline and recent earnings beat.

Axsome insider buys signal confidence but raise questions: COO’s $1.66M PSU purchase ahead of FDA decision may drive future upside for investors.

Axsome COO buys RSUs amid price dip—inside look at insider confidence, long‑term plans and what it means for investors.

Insider buying boosts optimism for Axsome’s pipeline, as Mark Coleman’s 6,250‑share purchase signals confidence in commercial growth and Phase 3 trials.